Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.15, delivering a surprise of 15.38%. Over the last four quarters, the company has surp ...

财务业绩 - 第二季度总收入为1.611亿美元，同比增长15.3%[4] - 软件订阅收入为1.364亿美元，同比增长15.8%[4] - 云收入为6630万美元，同比增长29.6%[4] - 年度经常性收入(ARR)为5.484亿美元，同比增长17.3%[4] - 每位直接客户的平均年度收入(AARPC)为12.357万美元[4] - 公司总收入为3.18亿美元，同比增长16.7%[46] - 软件订阅收入为2.68亿美元，同比增长17.2%[46] - 服务收入为4961万美元，同比增长13.8%[46] 盈利能力 - 非GAAP经营利润为3330万美元，同比增长83.9%[4] - 非GAAP净利润为2500万美元，非GAAP每股摊薄收益为0.15美元[4] - 调整后EBITDA为3850万美元，同比增长75%，调整后EBITDA利润率为23.9%[4] - 非GAAP毛利率为62.5%，同比提升1.6个百分点[27,28] - 非GAAP营业利润为1.06亿美元，同比增长46.9%[32] - 非GAAP净利润为7848万美元，同比增长213.8%[33] - 非GAAP每股摊薄收益为0.05美元，同比增长125%[34] - 经调整EBITDA为1.41亿美元，同比增长35.6%[35,37,38] - 经调整EBITDA利润率为44.4%，同比提升4.6个百分点[38] - 非GAAP经营收入为33,303千美元[71] - 非GAAP净收入为24,991千美元[73] - 非GAAP每股摊薄收益为0.15美元[74] - 调整后EBITDA为38,515千美元[77] - 调整后EBITDA利润率为23.9%[78] 现金流 - 自由现金流为8700万美元，同比增长48.7%[39,40] - 自由现金流为36,944千美元[80] - 自由现金流利润率为22.9%[80] 财务状况 - 公司在2024年6月30日的现金及现金等价物为3.26亿美元，较2023年6月30日的4.19亿美元增加了[57] - 公司在2024年6月30日的非GAAP毛利率为73.1%，较2023年6月30日的71.3%有所提升[60] - 公司在2024年6月30日的非GAAP研发费用为2616.4万美元，较2023年6月30日的2553.3万美元有所增加[66] - 公司在2024年6月30日的非GAAP销售及营销费用为7269.5万美元，较2023年6月30日的6384.7万美元有所增加[67] - 公司在2024年6月30日的非GAAP管理费用为5820.0万美元，较2023年6月30日的6254.4万美元有所下降[68] - 公司在2024年6月30日的非GAAP净利润为4842.2万美元，较2023年6月30日的2609.1万美元有所增加[60] - 公司在2024年6月30日的非GAAP每股摊薄收益为0.30美元，较2023年6月30日的0.16美元有所提升[60] - 公司在2024年6月30日的自由现金流为4144.6万美元，较2023年6月30日的-3179.9万美元有所改善[61] - 公司在2024年6月30日的自由现金流率为13.0%，较2023年6月30日的-11.7%有所提升[61] - 公司在2024年6月30日的调整后EBITDA为7525.8万美元，较2023年6月30日的4218.5万美元有所增加[60] 其他 - 预计第三季度收入为1.64亿美元至1.67亿美元，调整后EBITDA为3300万美元至3500万美元[7] - 预计全年收入为6.54亿美元至6.6亿美元，云收入增长28%，调整后EBITDA为1.39亿美元至1.45亿美元[7] - 公司发生了-1,575千美元的收购相关或有对价影响[77] - 公司发生了619千美元的裁员费用[77] - 公司发生了548千美元的交易成本[77]

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval. The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transacti ...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval. The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transacti ...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. "The second quarter financial results demonstrate the true earnings power of the Vertex business model," stated David DeStefano, Vertex's President, Chief Executive Officer and Chairperson of the Board. "We were GAAP earnings positive for the third quarter in a row, g ...

Shares of the rare disease drugmaker are already up more than 40% over the past year. Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (VRTX -3.55%). Shares of the biotech stock surged by 42% during the 12 months ended Aug 5. Now that it's already risen a great deal, investors are wondering if they've missed the boat on this stock. Can Vertex Pharmaceuticals stock keep rising in the years ahead or is i ...

文章核心观点 - 公司在第二季度出现了巨额亏损,但这主要是由于收购Alpine Immune Sciences公司而产生的一次性费用所致,并不反映公司的实际经营状况 [3][4][5] - 公司的核心业务仍保持良好增长,全年收入指引也有所上调 [9][10][11] - 公司未来有多个重要产品即将获批上市,有望成为新的增长引擎 [13][14][15] 公司业务概况 - 公司主要从事治疗性纤维化性疾病的药物研发和销售,其主导产品Trikafta/Kaftrio销售持续强劲 [2][4] - 公司通过收购Alpine Immune Sciences公司,获得了一款针对IgA肾病的新药物,有望拓展至其他自身免疫性肾脏疾病 [6][7] 财务表现 - 公司在第二季度出现了约36亿美元的净亏损,主要是由于收购Alpine公司产生的一次性费用 [3][5] - 剔除这一非经常性费用,公司第二季度实际利润约为8亿美元 [5] - 公司全年收入指引上调,主要得益于纤维化业务的持续增长以及新药物Casgevy的上市 [9][10][11] 未来发展 - 公司有两款重要新药物即将获批,包括治疗纤维化的vanzacaftor三联疗法和治疗急性疼痛的suzetrigine [13][14] - 公司还计划将suzetrigine拓展至糖尿病周围神经病变和腰椎神经根病等其他适应症 [15] - 总的来说,公司未来发展前景依然看好,仍是一只值得长期投资的优质生物科技股 [15]

The 2024 Mid-Year Sales Tax Rates and Rules report outlines the evolving landscape of local tax implementation, proliferation of fees, and increasing complexity of tax compliance for businesses across the U.S. This is reflected by a 67% year-over-year increase in city-level sales tax rate changes. "The landscape of sales tax and indirect taxation continues to change rapidly, both domestically and globally," said Michael Bernard, Vertex Chief Tax Officer. "The ongoing trend of cities and districts leveraging ...

Now, let's get back to our question. Could this smaller biotech follow in the footsteps of its bigger partner? Their paths are a bit different: Vertex focused on CF for a number of years, building a billion-dollar business that's allowed it to fund programs in other areas. CRISPR Therapeutics has been applying its technology across treatment areas in preclinical and clinical studies for some time. CRISPR Therapeutics could start reporting product revenue soon. Vertex remains an excellent investment, but inv ...

KING OF PRUSSIA, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Vertex, Inc. is a leading global provider of indirect tax solutions. The Company's mission is to deliver the most trusted tax technology ena ...